Hydroxytyrosol Improves 7 Biomarkers of Aging and Inflammation

Why This Study Matters

The health benefits of olive oil polyphenols are well-documented. But most of that research has a limitation: it studied polyphenols as a component of olive oil or as part of a Mediterranean diet. That makes it hard to separate the effect of the polyphenol from the effect of the overall diet.

This trial asked a more specific question: what happens when you isolate hydroxytyrosol -- the most potent olive polyphenol -- and give it to people as a standalone supplement at a defined dose? And not to healthy volunteers, but to the population that stands to benefit most: adults with overweight and prediabetes who are already at elevated risk for cardiovascular disease, type 2 diabetes, and age-related decline.

That's what makes this study worth paying attention to. It's not another observational study showing that people who eat Mediterranean diets live longer. It's a controlled experiment testing a specific compound, at a specific dose, in a specific at-risk population.

How It Was Designed

The basics are in the study design bar above: 49 participants, 16 weeks, 15 mg/day, randomized and placebo-controlled. But a few details stand out.

The trial was double-blinded -- participants, care providers, and investigators were all masked to group assignment. Most supplement studies are only double-blinded. Everyone received the same controlled olive oil (1 liter per week) as their only cooking fat, ensuring any differences came from the supplement alone. And rather than relying on participants to self-report whether they took their capsules, the researchers measured a hydroxytyrosol metabolite in urine to verify the compound was actually being absorbed (p = 0.039).

The study was also pre-registered on ClinicalTrials.gov before data collection began. That means the researchers committed to their outcome measures in advance -- they didn't collect data first and then decide which results to highlight.

What They Found

Compared to placebo, the hydroxytyrosol group showed statistically significant improvements across seven biomarkers:

Biomarker	HT Group	Placebo	p-value	What It Measures
oxLDL	-5.11 pg/mL	+29.69 pg/mL	0.045	Oxidized LDL cholesterol
Carbonyls	-0.45 ng/mL	+2.21 ng/mL	0.031	Protein oxidation
8-OHdG	-36.69 ng/mL	-8.13 ng/mL	< 0.01	DNA damage
TAS	+0.056 mmol/L	-0.04 mmol/L	< 0.01	Total antioxidant capacity
GPx	-3.85 U/L	-60.84 U/L	< 0.01	Glutathione peroxidase activity
IL-6	-2.31 pg/mL	-0.69 pg/mL	0.05	Chronic inflammation
GLP-1	-0.42 pM	+5.33 pM	0.014	Glucose regulation

Green indicates a favorable direction vs. placebo. All differences are statistically significant.

Reading the Results

The seven biomarkers group into four areas:

Oxidative damage to cholesterol, proteins, and DNA (oxLDL, carbonyls, 8-OHdG). Oxidized LDL is the form of cholesterol that actually drives plaque buildup in arteries -- it's a more specific cardiovascular risk marker than LDL alone. Carbonyls measure free radical damage to proteins. 8-OHdG measures oxidative damage to DNA and was the strongest result in the entire study. In all three markers, the hydroxytyrosol group improved while the placebo group worsened.

The body's own antioxidant defenses (TAS, GPx). This is an important distinction. TAS measures total antioxidant capacity. GPx (glutathione peroxidase) is an enzyme your body produces on its own -- it's part of your endogenous defense system, not something you get from a supplement. Over 16 weeks, the placebo group's GPx activity dropped significantly. The hydroxytyrosol group held steady. This suggests the compound supports the body's own antioxidant machinery rather than just adding external antioxidants on top.

Chronic inflammation (IL-6). IL-6 is one of the most studied markers of low-grade systemic inflammation -- the kind that doesn't cause symptoms but is associated with cardiovascular disease, metabolic dysfunction, and accelerated aging. The hydroxytyrosol group saw a significantly larger reduction than placebo.

Glucose regulation (GLP-1). GLP-1 is the pathway behind semaglutide (Ozempic). In people with prediabetes, the body often ramps up GLP-1 as a compensatory mechanism to manage blood sugar. The placebo group showed exactly this pattern -- a significant increase. The hydroxytyrosol group's GLP-1 stayed stable, which the researchers interpreted as a sign of more efficient glucose regulation without needing that compensatory response.

What Didn't Change

No significant differences in total cholesterol, LDL, HDL, triglycerides, weight, BMI, waist circumference, sleep, mental well-being, or physical capacity. No adverse events were reported. Hydroxytyrosol's mechanism of action in this study was specifically through antioxidant and anti-inflammatory pathways -- not metabolic or weight-related ones.

Broader Context

There are over 76 randomized controlled trials on hydroxytyrosol indexed on PubMed. The landmark PREDIMED trial demonstrated cardiovascular benefits from extra virgin olive oil rich in polyphenols. In 2011, the European Food Safety Authority (EFSA) authorized a health claim for olive oil polyphenols and the protection of blood lipids from oxidative damage -- one of the few such authorizations for any food-derived compound.

What sets this 2025 trial apart: it tested hydroxytyrosol in isolation, in capsule form, at a specific dose. Most prior research couldn't separate the polyphenol's effects from the broader benefits of olive oil or the Mediterranean diet. This study could.

Olivea's Dosage

This trial used 15 mg/day. Each Olivea capsule delivers over 20 mg of hydroxytyrosol per serving. Our most recent third-party certificate of analysis confirmed 23.5 mg per capsule.

We share this research for transparency. This is an independent study -- we did not fund it, design it, or conduct it.